^
Association details:
| Biomarker: | KIT exon 9 mutation |
|---|---|
| Cancer: | Gastrointestinal Stromal Tumor |
| Drug: | Qinlock (ripretinib) (c-KIT inhibitor, FLT3 inhibitor, PDGFR α inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Clinical activity of ripretinib in patients with advanced gastrointestinal stromal tumor harboring heterogenous KIT/PDGFRA mutations in the phase 3 INVICTUS study
Published date:
09/09/2021
Excerpt:
Patients receiving ripretinib demonstrated progression-free survival (PFS) benefit vs placebo regardless of mutation status (hazard ratio 0.16) and in all assessed subgroups in Kaplan-Meier PFS analysis (exon 11, P <0.0001; exon 9, P=0.0023; exon 13, P <0.0001; exon 17, P <0.0001)....Ripretinib provided clinically meaningful activity across mutation subgroups in patients with advanced GIST...
DOI:
10.1158/1078-0432.CCR-21-1864
Trial ID:
